Associations of Peak-Width Skeletonized Mean Diffusivity and Post-Stroke Cognition

Angela C C Jochems1, Susana Muñoz Maniega1, Una Clancy1

  • 1Centre for Clinical Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, Edinburgh EH16 4SB, UK.

Life (Basel, Switzerland)
|September 23, 2022
PubMed

Insights

Peak-width of Skeletonized Mean Diffusivity (PSMD), a marker of white matter health, is linked to cognitive function after stroke. Higher PSMD at one year post-stroke predicts lower cognitive scores, suggesting its potential for predicting long-term impairment.

Area of Science:

  • Neuroimaging
  • Neurology
  • Cognitive Science

Background:

  • Post-stroke cognitive impairment significantly impacts patient recovery and quality of life.
  • Peak-width of Skeletonized Mean Diffusivity (PSMD) is an emerging diffusion imaging biomarker reflecting white matter integrity.
  • Understanding factors influencing cognitive decline after stroke is crucial for developing effective interventions.

Purpose of the Study:

  • To investigate the association between PSMD and global cognitive function in patients with mild ischemic stroke.
  • To examine cognitive changes at 3 months and 1 year post-stroke in relation to PSMD.
  • To determine if baseline PSMD can predict cognitive outcomes at 1 year.

Main Methods:

  • Cross-sectional analysis of mild ischemic stroke patients (N=229 at 3 months, N=173 at 1 year).
  • Assessment of global cognition using the Montreal Cognitive Assessment (MoCA).
  • Statistical adjustment for covariates including premorbid IQ, age, sex, stroke severity, and disability.

Main Results:

  • At 3 months, PSMD was not significantly associated with MoCA scores.
  • At 1 year, higher PSMD was significantly associated with lower MoCA scores (βstandardized = −0.301, p < 0.001).
  • Higher baseline PSMD predicted lower MoCA scores at 1 year (βstandardized = −0.182, p = 0.005).

Conclusions:

  • The association between PSMD and global cognition strengthens over time after stroke, becoming significant at 1 year.
  • PSMD in the subacute phase may serve as a predictor of long-term cognitive impairment following mild ischemic stroke.
  • This finding highlights the utility of PSMD as a potential imaging biomarker for cognitive outcomes in stroke survivors.

Related Concept Videos